These findings have led to the changing of the current therapeutic algorithm of advanced NSCLC, adding a new standard first-line treatment option for patients with PD-L1-positive tumors [11], combination regimens of CTX and IT, and also as a second-line option after an initial CTX regimen. Here, CD274 is linked to non-small cell lung carcinoma.